Sachin Katyal, University of Manitoba

Research

Brain Tumours Cancer Genetics Chemoradiotherapy Chemotherapy Malignant Glioma Mouse Models Novel Therapeutics Radiotherapy

Latest papers

Integrated genetic screening identifies FEN1 as a selective vulnerability and temozolomide resistance mediator in glioblastoma stem cells
Cancer Research Communications · 2026
ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells.
Blood advances · 2025 · senior author
Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.
Current oncology (Toronto, Ont.) · 2023

All 14 publications

Latest funding

ATM and TDP1 coordinate neurodevelopment and modulate Top1-mediated anti-cancer therapeutic outcome
CIHR · 2014 · Nominated PI
$817,320
Modulation of the DNA damage repair (DDR) response in the treatment of brain tumours
CIHR · 2014 · Nominated PI
$300,000

All 2 grants and awards

14 publications.

01

Integrated genetic screening identifies FEN1 as a selective vulnerability and temozolomide resistance mediator in glioblastoma stem cells

Brakel BA, McKenna D, Puri A, Shaikh MV, Singh M, Saleh A, Tomajian A-J, Mikolajewicz N, Beltrami M, Topley M

Cancer Research Communications2026

DOI: 10.1158/2767-9764.crc-26-0150

02

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells.

Kost SEF, Saleh A, Brown J, Yuan SH, Kuzio B, Yang L, Banerji V, Gibson SB, Johnston JB, Katyal S

Blood advances2025Senior author

DOI: 10.1182/bloodadvances.2024014407 PMID: 39969198

03

Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.

Yang J, Yang L, Tordon B, Bucher O, Nugent Z, Landego I, Bourrier N, Uminski K, Brown K, Squires M, Marshall AJ, Katyal S, Mahmud S, Decker K, Geirnaert M, Dawe DE, Gibson SB, Johnston JB, Banerji V

Current oncology (Toronto, Ont.)2023

DOI: 10.3390/curroncol30070472 PMID: 37504332

04

Venetoclax inhibits autophagy in chronic lymphocytic leukemia cells.

Chen Y, Kost SEF, Yang X, Banerji V, Johnston JB, Katyal S, Gibson SB

Autophagy reports2023

DOI: 10.1080/27694127.2023.2169518 PMID: 40395294

05

DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease.

Kost SEF, Saleh A, Yuan SH, Kuzio B, Gibson SB, Yang L, Banerji V, Johnston JB, Katyal S

Blood cancer journal2023Senior author

DOI: 10.1038/s41408-022-00781-8 PMID: 36707503

06

Chromatin architecture at susceptible gene loci in cerebellar Purkinje cells characterizes DNA damage-induced neurodegeneration.

Kwak YD, Shaw TI, Downing SM, Tewari A, Jin H, Li Y, Dumitrache LC, Katyal S, Khodakhah K, Russell HR, McKinnon PJ

Science advances2021

DOI: 10.1126/sciadv.abg6363 PMID: 34910524

07

PARP-DNA trapping ability of PARP inhibitors jeopardizes astrocyte viability: Implications for CNS disease therapeutics.

Sinha A, Katyal S, Kauppinen TM

Neuropharmacology2021

DOI: 10.1016/j.neuropharm.2021.108502 PMID: 33631119

08

RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status

Sinha A, Saleh A, Endersby R, Yuan SH, Chokshi CR, Brown KR, Kuzio B, Kauppinen T, Singh SK, Baker SJ

Cancers202018 citationsSenior author

DOI: 10.3390/cancers12113178

09

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia.

Kost SEF, Saleh A, Mejia EM, Mostafizar M, Bouchard EDJ, Banerji V, Marshall AJ, Gibson SB, Johnston JB, Katyal S

Cancers2019Senior author

DOI: 10.3390/cancers11101519 PMID: 31601046

10

The BH3 only Bcl-2 family member BNIP3 regulates cellular proliferation.

Singh A, Azad M, Shymko MD, Henson ES, Katyal S, Eisenstat DD, Gibson SB

PloS one2018

DOI: 10.1371/journal.pone.0204792 PMID: 30307949

ATM and TDP1 coordinate neurodevelopment and modulate Top1-mediated anti-cancer therapeutic outcome

Nominated PICIHR2014Operating Grant

Principal investigators: Katyal, Sachin

Keywords: Brain Tumours; Cancer Genetics; Chemoradiotherapy; Chemotherapy; Malignant Glioma; Mouse Models; Neurodegenerative Disease; Novel Therapeutics; Radiotherapy; Topoisomerase

$817,320

Modulation of the DNA damage repair (DDR) response in the treatment of brain tumours

Nominated PICIHR2014CIHR New Investigator

Principal investigators: Katyal, Sachin

Keywords: Brain Tumours; Cancer Genetics; Chemoradiotherapy; Chemotherapy; Malignant Glioma; Medulloblastoma; Mouse Models; Novel Therapeutics; Radiotherapy; Topoisomerase

$300,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Pharmacology and Therapeutics
Immunology
Surgery
Genetics and Genome Biology
Community Health Sciences
Internal Medicine

Co-authors at University of Manitoba, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.

Jason Moffat

Genetics and Genome Biology

1 shared papers, latest 2026

Kathleen Decker

Community Health Sciences

1 shared papers, latest 2023

Meghan Azad

Internal Medicine

1 shared papers, latest 2018

Tiina Kauppinen

Pharmacology and Therapeutics

1 shared papers, latest 2020

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mention

Subject: Prospective PhD student: Brain Tumours Dear Professor Katyal, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Integrated genetic screening identifies FEN1 as a selective vulnerability and temozolomide resistance mediator in glioblastoma stem cells" (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Sachin Katyal